FDC Limited (NSE:FDC)
India
· Delayed Price · Currency is INR 490.25
+14.40 (3.03%)
Jun 16, 2025, 3:29 PM IST
FDC Limited Revenue
In the fiscal year ending March 31, 2025, FDC Limited had annual revenue of 21.08B INR with 8.50% growth. FDC Limited had revenue of 4.92B in the quarter ending March 31, 2025, with 6.46% growth.
Revenue
21.08B
Revenue Growth
+8.50%
P/S Ratio
3.68
Revenue / Employee
3.17M
Employees
6,659
Market Cap
77.52B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 21.08B | 1.65B | 8.50% |
| Mar 31, 2024 | 19.43B | 1.59B | 8.92% |
| Mar 31, 2023 | 17.84B | 2.56B | 16.74% |
| Mar 31, 2022 | 15.28B | 1.95B | 14.61% |
| Mar 31, 2021 | 13.33B | -109.88M | -0.82% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 271.45B |
| Apollo Hospitals Enterprise | 217.94B |
| Mankind Pharma | 122.07B |
| Zydus Lifesciences | 232.42B |
| Aurobindo Pharma | 317.24B |
| Alkem Laboratories | 129.65B |
FDC Limited News
- 18 days ago - FDC shares drop over 3% as Q4 EBITDA falls 4.2% YoY to Rs 54 crore, net profit down 16.4% YoY - Business Upturn
- 6 months ago - FDC receives US FDA approval for Cefixime 400 mg tablets - Business Upturn
- 9 months ago - FDC shares surge 11%, leading gains in BSE Healthcare index - Business Upturn